970*90
768
468
mobile

Lupin gets USFDA nod for psoriasis treatment spray

Franchise India Bureau
Franchise India Bureau Mar 19 2018 - 1 min read
Lupin gets USFDA nod for psoriasis treatment spray
It is a generic version of Taro Pharmaceuticals USA Inc.'s Topicort Topical Spray, 0.25 per cent.

Drug major Lupin has received approval from the US health regulator to market Desoximetasone Topical spray, a formulation for treatment of plaque psoriasis, in the American market.

It is a generic version of Taro Pharmaceuticals USA Inc.'s Topicort Topical Spray, 0.25%.

The approval has been granted to the product in the size of 30 ml, 50 ml, and 100 ml.

Lupin in a BSE filing said it has received final approval for the spray, 0.25%, from the United States Food and Drug Administration (USFDA).

As per IQVIA MAT data of January 2018, the product had annual sales of around USD 19.5 million in the US.

Shares of Lupin were trading up 1.12% at Rs.770.75 apiece on BSE.

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online

Newsletter Signup

Share your email address to get latest update from the industry